Published in J Exp Med on February 18, 2002
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2004) 2.34
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol (2009) 2.10
Conditional immortalization of human B cells by CD40 ligation. PLoS One (2008) 1.89
Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol (2006) 1.43
Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J Mol Biol (2007) 1.36
Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J Exp Med (2002) 1.25
Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. Eur J Immunol (2007) 1.24
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A (2004) 1.21
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting. J Biol Chem (2012) 0.96
Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nat Protoc (2014) 0.95
Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. Cancer Immunol Immunother (2010) 0.95
Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat (2008) 0.92
MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs. J Immunol (2010) 0.92
Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA. Mol Ther (2010) 0.87
HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. Blood (2011) 0.87
Specific roles of each TCR hemichain in generating functional chain-centric TCR. J Immunol (2015) 0.84
In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells. J Immunol Methods (2010) 0.83
Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis. Blood (2013) 0.82
Melanoma-associated leukoderma - immunology in black and white? Pigment Cell Melanoma Res (2013) 0.82
Reduced naïve CD8(+) T-cell priming efficacy in elderly adults. Aging Cell (2015) 0.82
Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination. J Biomed Biotechnol (2010) 0.79
A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma. Clin Dev Immunol (2013) 0.77
Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation. Immunology (2015) 0.76
Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol (2017) 0.75
Far East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: Yersinia pseudotuberculosis-Derived Mitogen A. Open Forum Infect Dis (2015) 0.75
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol (2001) 9.23
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell (1991) 6.49
The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity (1999) 6.10
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Selecting and maintaining a diverse T-cell repertoire. Nature (1999) 5.35
A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today (1998) 5.07
Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med (2000) 5.07
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol (1998) 4.68
Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med (2000) 4.54
Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med (1999) 4.27
Cutting edge: naive T cells masquerading as memory cells. J Immunol (2000) 4.27
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med (2000) 3.70
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med (1998) 3.04
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98
Designing and maintaining the mature TCR repertoire: the continuum of self-peptide:self-MHC complex recognition. Immunity (1999) 2.89
Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc Natl Acad Sci U S A (1995) 2.77
Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity (2000) 2.71
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol (1998) 2.68
High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med (1998) 2.58
Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J Exp Med (1994) 2.56
Self-ignorance in the peripheral T-cell pool. Immunol Rev (1993) 1.73
Direct evidence for thymic function in adult humans. J Exp Med (1999) 1.70
Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol (1997) 1.52
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med (1996) 1.38
Requirement for diverse, low-abundance peptides in positive selection of T cells. Science (1999) 1.36
Preferential rearrangements of the T cell receptor-delta-deleting elements in human T cells. J Immunol (1997) 1.36
Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J Immunol (2000) 1.31
Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol (2001) 1.24
Self-antigen presentation by thymic stromal cells: a subtle division of labor. Curr Opin Immunol (2000) 1.21
Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol (1996) 1.20
A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol (2000) 1.18
Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res (2001) 1.08
HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol (2001) 1.05
Identical expression of CD45R isoforms by CD45RC+ 'revertant' memory and CD45RC+ naive CD4 T cells. Immunology (1997) 1.00
Contribution of individual amino acids within MHC molecule or antigenic peptide to TCR ligand potency. J Immunol (2000) 0.99
The thymus and central tolerance. Philos Trans R Soc Lond B Biol Sci (2001) 0.97
Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur J Immunol (2000) 0.97
Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. Cancer Res (2001) 0.96
T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J Immunol (2000) 0.96
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res (1998) 0.95
CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin Cancer Res (2001) 0.91
A simplified procedure for the preparation of MHC/peptide tetramers: chemical biotinylation of an unpaired cysteine engineered at the C-terminus of MHC-I. J Immunol Methods (2000) 0.91
Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res (2001) 0.90
Random entry of circulating lymphocyte subsets into peripheral lymph nodes and Peyer's patches: no evidence in vivo of a tissue-specific migration of B and T lymphocytes at the level of high endothelial venules. Eur J Immunol (1992) 0.83
The Pathway Tools software. Bioinformatics (2002) 14.89
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Notch regulation of lymphocyte development and function. Nat Immunol (2004) 3.39
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med (2004) 3.16
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Endothelial progenitor cells: identity defined? J Cell Mol Med (2009) 2.96
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry (2005) 2.94
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88
The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol (2008) 2.87
Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early alpha beta Lineage Thymocytes. Immunity (2002) 2.83
Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell (2008) 2.83
The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol (2007) 2.59
Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. Blood (2004) 2.44
Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat Immunol (2004) 2.40
Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. Immunity (2010) 2.29
Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci U S A (2009) 2.27
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A (2006) 2.19
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum (2008) 2.15
Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. J Infect Dis (2011) 2.12
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol (2007) 1.95
Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry (2007) 1.93
EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming. J Biol Chem (2006) 1.91
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Precursors of functional MHC class I- or class II-restricted CD8alphaalpha(+) T cells are positively selected in the thymus by agonist self-peptides. Immunity (2002) 1.83
Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol (2005) 1.82
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol (2009) 1.81
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
D²P²: database of disordered protein predictions. Nucleic Acids Res (2012) 1.75
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells. J Immunol (2002) 1.71
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A (2007) 1.65
Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood (2012) 1.65
Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections. BMC Infect Dis (2010) 1.64
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 1.61
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58
Regulation of innate and adaptive immunity by Notch. Nat Rev Immunol (2013) 1.58
Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun (2006) 1.58
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol (2013) 1.57
Rational drug design via intrinsically disordered protein. Trends Biotechnol (2006) 1.57
Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 1.55
In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest (2003) 1.54
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51
Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J Immunol (2009) 1.51
Improving protein order-disorder classification using charge-hydropathy plots. BMC Bioinformatics (2014) 1.50
Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia. Nat Immunol (2010) 1.49
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48